Compare KMX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | MIRM |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.2B |
| IPO Year | 2002 | 2019 |
| Metric | KMX | MIRM |
|---|---|---|
| Price | $58.53 | $99.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $37.18 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 2.3M | 716.0K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $25,881,131,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | $1.82 | $22.04 |
| P/E Ratio | $45.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.40 | $63.23 |
| 52 Week High | $62.56 | $130.00 |
| Indicator | KMX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 41.48 |
| Support Level | $56.22 | $88.08 |
| Resistance Level | $61.13 | $107.51 |
| Average True Range (ATR) | 1.77 | 4.46 |
| MACD | -0.13 | -0.55 |
| Stochastic Oscillator | 67.34 | 48.05 |
CarMax sells, finances, and services used and new cars through a chain of over about 260 retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 80% of fiscal 2026 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2026, the company retailed and wholesaled 780,684 and 538,203 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US, but still estimates that it had only about 3.6% US market share of vehicles zero to 10 years old in calendar 2025. CarMax is based in Richmond, Virginia.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.